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Abstract
Background: Antiplatelet and anticoagulant therapy are commonly used before, during and after peripheral arterial
endovascular intervention. This survey aimed to establish antiplatelet and anticoagulant choice for peripheral
arterial endovascular intervention in contemporary clinical practice.
Methods: Pilot-tested questionnaire distributed via collaborative research networks.
Results: One hundred and sixty-two complete responses were collected from responders in 22 countries,
predominantly the UK (48%) and the rest of the European Union (44%). Antiplatelet monotherapy was the most
common choice pre-procedurally (62%). In the UK, there was no difference between dual and single antiplatelet
therapy use post procedure (50% vs. 37% p = 0.107). However, a significant majority of EU respondents used dual
therapy (68% vs. 20% p < 0.001). There was variation in choice of antiplatelet therapy by the device used and the
anatomical location of the intervention artery. The majority (82%) of respondents believed there was insufficient
evidence to guide antithrombotic therapy after peripheral endovascular intervention and most (92%) would
support a randomised trial.
Conclusions: There is widespread variation in the use of antiplatelet therapy, especially post peripheral arterial
endovascular intervention. Clinicians would support the development of a randomised trial comparing dual
antiplatelet therapy with monotherapy.
Keywords: Platelet Aggregation Inhibitors, Peripheral Arterial Disease, Endovascular Procedures, Surveys and
Questionnaires
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Background
Antiplatelet therapy is commonly used before, during
and after peripheral arterial endovascular intervention. It
is reccomended in guidelines; predominantly due to a
reduction in cardiovascular events (Conte et al. 2019;
National Institute for Health and Care Excellence 2015).
However the clinical benefit to support the use of spe-
cific antiplatelet regimens, even for ‘established’ indica-
tions such as a reduction in cardiovascular events, is
actually marginal (Ambler et al. 2019). As a result,
guidelines are conflicted as they interpret the evidence
differently (Conte et al. 2019; National Institute for
Health and Care Excellence 2015). The evidence for
maintenance of lower limb bypass patency (Ambler et al.
2019) and when used following coronary intervention
(Levine et al. 2016) is more established. This is probably
why randomised trials examining new technologies for
use in the peripheral arteries have mandated the use of
dual antiplatelet therapy in the intervention arms, but
not always the comparator arm (Krankenberg et al.
2007). Perhaps as a result the use of dual antiplatelet
therapy after peripheral endovascular intervention has
become more prevalent in clinical practice. Add in the
constantly emerging evidence in cardiology (Levine et al.
2016), and well publicised trials of direct oral anticoagu-
lants for non-intervened peripheral arterial disease
(Anand et al. 2018), and it has become even more con-
fusing for peripheral endovascular practitioners. The
benefits of any change in drug regimen or new drug
have to be balanced against the risks they pose and the
cost (Ambler et al. 2019). When compared to cardiology
there is a huge gap in our knowledge for antiplatelet
therapy choice around peripheral arterial endovascular
intervention; a high-volume procedure which is becoming
more common (Cull et al. 2010). The aim of this survey
was to establish contemporary practice for antiplatelet and
or antithrombotic therapy to inform a clinical trial design
comparing antiplatelet or antithrombotic agents after
peripheral arterial endovascular intervention.
Methods
As no validated reporting guidelines for surveys exist, we
followed the 38 point checklist generated from a system-
atic review of published guidance and reporting practice
(Bennett et al. 2011). The survey was designed by the au-
thors (KW, DCB, RJH, CPT) and piloted on 7 vascular
surgeons and 2 vascular interventional radiologists at
North Bristol NHS Trust. A final 9 item survey was de-
fined (Additional file 1).
Survey protocol, inclusion criteria and dissemination
The United Kingdom based trainee collaborative VERN
(Vascular and Endovascular Research Network) agreed
to disseminate the survey (Bosanquet et al. 2016). A
predefined protocol was specified for the survey and made
available on the VERN website (available at https://vascu-
lar-research.net/projects/considering-leading-experts-anti
thrombotic-regimes-after-peripheral-angioplasty-clear-sur
vey/ and included as Additional file 1). This defined the
surveyors as any grade in training and respondents as con-
sultant (or equivalent level) vascular interventional radiol-
ogists and vascular surgeons working in a centre treating
vascular patients. To ensure responses were from consul-
tants and to eliminate duplication, the email addresses of
the respondents were collected. To qualify for collabora-
tive authorship surveyors had to collect and input 5
responses. The survey was distributed as an online Survey-
Monkey form via the VERN emailing list. Social media
was used for advertising. Vascupedia, the Rouleaux Club,
Association of Surgeons in Training (ASIT), and STAR
Surg also distributed the survey via their emailing list. The
survey was open from 22nd July to 29th August 2019.
Data were coded, collected and stored anonymously on
encrypted devices.
Statistical analysis
Incomplete responses were removed during data clean-
ing. Five percent of the complete responses were ran-
domly selected and independently verified by directly
contacting the responder; correlation was 100%. Cat-
egorical data are presented as counts and percentages
per group. Statistical comparisons were performed via a
predetermined protocol. Significant differences between
categorical variables were determined via Chi-squared
tests in Excel (Microsoft, version 16.16.4). Results were
further analysed and compared by dividing the sample
into geographical subgroups if sufficient responses (> 50)
were collected. Responses to questions about antithrom-
botic therapy for different arterial levels were modelled
using a mixed effects logistic regression model with a
random intercept and fixed slope using the ‘lme4’ pack-
age in the R statistical programming environment. The
model compared a preference for dual antiplatelet ther-
apy over monotherapy, with participants who expressed
a preference for other options removed. All statistical
tests were 2-sided with a 0.05 level of significance.
Results
One hundred and eighty-three responses were received
from discrete responders, obtained by 71 surveyors.
Twenty-one were incomplete, leaving 162 complete re-
sponses. Of these, 78 (48%) were from the UK, 71 (44%)
from other European Union (EU) countries and 13 (8%)
from other countries (Fig. 1). The exact response rate to
the questionnaire was impossible to calculate because of
the way the survey was distributed using research net-
works and social media. It was also not possible to cal-
culate the number of consultants and trainees included
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in the emailing lists as this information was not rou-
tinely captured.
Pre-procedural antithrombotic therapy
Antiplatelet monotherapy was the most popular choice
for pre-procedural antithrombotic therapy from 62% of
respondents (Fig. 2a). Aspirin was used most frequently
(44%) while clopidogrel was preferred by 18%. The ma-
jority of respondents would continue aspirin or clopido-
grel monotherapy for the procedure (98% and 80%
respectively), while most would stop Warfarin and direct
oral anticoagulants (94% and 95%). Fifty one percent
would change from dual therapy to monotherapy; this
was significantly higher in the UK group compared to
the EU group (60% vs. 41%, p = 0.018). Most (99%) of re-
spondents used a loading dose of unfractionated heparin
intraprocedurally. Four (3%) would additionally give as-
pirin, clopidogrel or dual antiplatelet therapy.
Post procedural antithrombotic therapy
Overall, more respondents would use dual antiplatelet
therapy (58%) than monotherapy (30%) after an inter-
vention (p < 0.001). Anticoagulants were not used in iso-
lation by any responders but were used by 5% in
conjunction with dual antiplatelet therapy. In the UK,
there was no difference between dual and monotherapy
use post procedure (50% vs. 37% p = 0.107). However, a
significant majority of EU respondents used dual therapy
(68% vs 20% p < 0.001).
Antithrombotic differences by procedure and anatomical
location
Antiplatelet monotherapy was more commonly pre-
ferred following plain balloon angioplasty, while dual
therapy was more commonly preferred following every
other type of endovascular treatment (Fig. 3a; p < 0.001
all comparisons). Interestingly, this was different to the
preferences seen when asking generally about antithrom-
botic therapy post procedurally (Fig. 2b). Antiplatelet
monotherapy was preferred by a higher proportion of re-
spondents in the UK compared to the EU after drug-
coated balloon angioplasty (36% vs 21%, p = 0.047).
Monotherapy was preferred over dual antiplatelet ther-
apy for iliac artery intervention (63% vs 35%, p < 0.001),
while dual therapy was preferred for more distal lesions
(Fig. 3b). Mixed-effects modelling revealed that this
trend towards dual therapy was significant, with an odds
ratio of 5.8 in favour of dual therapy per anatomical level
of artery treated more distally (95% confidence interval
3.5–11.3, p < 0.001).
Rationale for antithrombotic choice
The majority (84%) of respondents chose antiplatelet
therapy because of perceived improvements in patency
rates (Fig. 4). The EU respondents chose this option
significantly more frequently (94% vs. 73% p < 0.001).
Procedural success was the next most frequent rationale
(51%). Factors listed as ‘other’ were: Reduction in myo-
cardial infarction (Conte et al. 2019); bleeding risk (Na-
tional Institute for Health and Care Excellence 2015);
patient preference (Conte et al. 2019); pre-operative
Fig. 1 Respondents country of work
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condition (Conte et al. 2019); cost (Conte et al. 2019)
and according to local expert advice (National Institute
for Health and Care Excellence 2015). The majority
(82%) of respondents believed there was insufficient evi-
dence to guide antithrombotic therapy after peripheral
endovascular intervention. This was higher in the UK
than the EU (90% vs. 73% p = 0.009). The majority (92%)
would be interested in participating in a randomised trial
on this topic.
Discussion
Internationally, dual antiplatelet therapy is now chosen
more commonly than monotherapy after peripheral ar-
terial endovascular intervention. UK based respondents
used single and dual therapy equally, while the rest of
the EU used dual therapy more commonly. Dual anti-
platelet therapy is used significantly more commonly
after more distal interventions. There was a difference in
how responders chose antiplatelet regimens when asked
about newer devices (such as drug coated or eluting
devices), with dual therapy being chosen more fre-
quently. This may have been influenced by the early
company sponsored randomised trials (Krankenberg
et al. 2007), which specified dual therapy when the de-
vices were being used but not necessarily in the control
arm. The instructions for use for several major devices
also recommend post procedural dual antiplatelet ther-
apy. Again, the reason is unclear. These choices may
have contributed to the current clinical confusion and
increased use of dual therapy after newer devices. Dual
therapy was more commonly chosen as interventions be-
came more distal, which is probably a reflection of the
concern raised by responders about loss of patency. Pa-
tency is not necessarily related to limb loss, but it is the
most commonly used surrogate outcome in randomised
trials in the peripheral vasculature as it is easy to power
a relatively small sample size, and it is easy to measure.
As a result, responders tend to think in terms of patency
(84% of responders) post intervention and not in terms
of patient-centred outcomes. The widespread use of dual
Fig. 2 Respondent preference for pre (a) and post (b) procedural antithrombotic therapy. Legend: DAPT dual antiplatelet therapy. DOAC direct
oral anticoagulant. *Monotherapy = composite of aspirin, clopidogrel and ‘other regime’ where an antiplatelet agent was specified
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Fig. 4 Rationale for antithrombotic choice
Fig. 3 Antithrombotic therapy stratified by procedure (a) and anatomical location (b). Legend: DAPT dual antiplatelet therapy. DOAC direct oral
anticoagulant. PBA Plain balloon angioplasty. BMS Bare metal stent. DCB Drug coated balloon. DES Drug eluting stent. CS Covered stent.
*Monotherapy = composite of aspirin, clopidogrel and ‘other regime’ where an antiplatelet agent was specified
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antiplatelet therapy is a concern because of the lack of
evidence of benefit but clear evidence of harm (Ambler
et al. 2019). For example, in all randomised trials com-
paring dual with mono antiplatelet therapy for periph-
eral arterial disease, dual antiplatelet therapy caused 37
more major bleeds per 1000 patients than monotherapy
(P < 0.001) but did not clearly improve any post endovas-
cular clinical outcome (Ambler et al. 2019). The Vascu-
lar community is behind cardiology in this respect, as
there are a number of trials examining antiplatelet ther-
apy after peripheral coronary intervention. While it is
tempting to draw practice from these trials it is bad sci-
ence to do so because of the differences between the
flow dynamics in the coronary and peripheral arteries,
and the differences in clinical sequelae of loss of patency
in the heart and in the leg. The limitations of the survey
include not stipulating a certain number of entries from
a country to be included in the final analysis, non-
response bias (which is a potential flaw in any survey or
questionnaire), and response bias in that people who are
using the antiplatelet regimes chosen may be more likely
to be involved in the questionnaire. These biases should
have been reduced by the study design, where surveyors
chose respondents rather than respondents being self-
selected. There will have been a proportionally higher
number of responses from the UK because the distribu-
tion lists used were predominantly based in the UK. The
other EU countries group was comprised of a low num-
ber of responses from a large number of countries. This
means that while it is not a true ‘EU’ position the group-
ing is useful to highlight that there are differences in UK
practice which would need to be taken into account for
any randomised trial. There was a lack of information
on doses of drugs in certain areas such as intraproce-
dural heparin. This was intentional to pragmatically keep
the questionnaire relatively quick to complete but would
have added interesting additional information.
Conclusions
There is widespread variation in the use of antiplatelet
therapy, especially following peripheral arterial endovas-
cular intervention. Preferences differed by device used
and anatomical site of procedure. The majority of inter-
ventional radiologists and surgeons agreed that there
was insufficient evidence to make robust antiplatelet re-
gime choices post endovascular intervention and would
support a randomised trial.
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Additional file 1: Figure S1. Published protocol and final survey.
Additional file 2: Table S1. Full data tables for responses.
Abbreviations
EU: European Union; UK: United Kingdom; VERN: Vascular and Endovascular
Research Network
Acknowledgements
Survey collaborators: Aldo Betanco, Andrea Mingoli, Andrej Isaak, Andrew
Holden, Andrew Tambyraja, Angeliki Argyriou, Anthony Dean Godfrey, Ashraf
Hassouna, Athanasios Diamantopoulos, Athanasios Saratzis, Atif Sharif, Ayoola
Awopetu, Brennig Gwilym, Calvin Eng, Carlo Maturi, Charutha Senaratne,
Christopher Graham, Colin Oliver, Coscas Raphael, Cristina L. Espada, Eamon
Kavanagh, Eckhard Klenk, Efthymios Beropoulis, Esau Martinez, Eustratia
Mpaili, Fabio Verzini, Fernando Gallardo, Gabriele Piffaretti, Gianni Celoria,
Gladiol, Gonzalo P. Tapia, Greta Saggu, Hannah Travers, James Gordon-Smith,
James Kirk, James Olivier, Jason Chuen, Jennifer Buxton, Jiber Hamid, John
Quarmby, Jonathan Nicholls, Konstantinos Stavroulakis, Laura Drudi, Marco V.
Usai, Mariano Rotger, Michael Gawenda, Mihai Ionac, Muayyad Almuhdhafer,
Ng Jun Jie, Nicola Troisi, Nikesh Dattani, Nikolaos Patelis, Paolo Sapienza,
Pasqualino Sirignano, Pierfrancesco Lapolla, Raveen Nijjer, Rengarajan
Rajagopal, Roberto farraresi, Rodrigo biagioni, Rohan Pancharatnam, Sandeep
Bahia, Simona Sica, Staros Spiliopoulos, Stefano Fazzini, Tanya Moledina,
Tasleem Akhtar, Thomas Aherne, Thomas Broszey, Tony Moloney.
The authors would like to thank all consultant surgeons and interventional
radiologists who took part in this survey. The dissemination of this study in
the UK and abroad would not have been possible without the support of
the Rouleaux Club (UK vascular trainees’ association), STARSurg (student
research collaborative), Vascupaedia, and the Association of Surgeons in
Training (ASiT).
The Vascular and Endovascular Research Network (VERN), UK
Authors’ contributions
KW DB and CT were involved in the design, piloting and dissemination of
the survey and writing the manuscript. GA was involved in statistical analysis
and writing the manuscript. MQ and RH were involved in writing the
manuscript. All authors read and approved the final manuscript.
Funding
GA, MQ and RH were supported by the NIHR Biomedical Research Centre at
University Hospitals Bristol NHS Foundation Trust and the University of
Bristol.
CT was supported by Research and Development at North Bristol NHS trust.
Availability of data and materials
The full anonymised survey result dataset is included as a Additional file 2.
Ethics approval and consent to participate
Not applicable: Ethics approval was not required as this was a survey of
clinicians. Collaborative authorship was predetermined as any surveyor who
contributed 5 distinct responses from different consultants during the data
collection period.
Consent for publication
Not applicable.
Competing interests
The authors declare they have no competing interests.
Received: 24 September 2019 Accepted: 24 October 2019
References
Ambler GK, Waldron CA, Contractor UB, Hinchliffe RJ, Twine CP (2019)
Antiplatelet therapy for peripheral arterial disease: an umbrella review and
meta-analysis of preventative and treatment outcomes. Br J Surg (in press)
Anand S, Bosch J, Eikelboom J et al (2018) Rivaroxaban with or without aspirin in
patients with stable peripheral or carotid artery disease: an international,
randomised, double-blind, placebo-controlled trial. Lancet 391:219–229.
https://doi.org/10.1016/s0140-6736(17)32409-1
Bennett C, Khangura S, Brehaut J et al (2011) Reporting guidelines for survey
research: an analysis of published guidance and reporting practices. PLoS
Med 8:e1001069. https://doi.org/10.1371/journal.pmed.1001069
Wong et al. CVIR Endovascular            (2019) 2:37 Page 6 of 7
Bosanquet D, Stather P, Sidloff D et al (2016) How to engage in trainee-led
multicentre collaborative vascular research: the vascular and endovascular
research network (VERN). Eur J Vasc Endovasc Surg 52:392. https://doi.org/10.
1016/j.ejvs.2016.07.001
Conte M, Bradbury A, Kolh P et al (2019) Global vascular guidelines on the
Management of Chronic Limb-Threatening Ischemia. Eur J Vasc Endovasc
Surg 58:S1–S109.e33. https://doi.org/10.1016/j.ejvs.2019.05.006
Cull D, Langan E, Gray B et al (2010) Open versus endovascular intervention for
critical limb ischemia: a population-based study. J Am Coll Surg 210:555–561.
https://doi.org/10.1016/j.jamcollsurg.2009.12.019
Krankenberg H, Schlüter M, Steinkamp H et al (2007) Nitinol stent implantation
versus percutaneous Transluminal angioplasty in superficial femoral artery
lesions up to 10 cm in length. Circulation 116:285–292. https://doi.org/10.
1161/circulationaha.107.689141
Levine G, Bates E, Bittl J et al. (2016) 2016 ACC/AHA Guideline Focused Update
on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery
Disease: A Report of the American College of Cardiology/American Heart
Association Task Force on Clinical Practice Guidelines: An Update of the 2011
ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011
ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/
AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and
Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/
AHA Guideline for the Management of ST-Elevation Myocardial Infarction,
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-
Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on
Perioperative Cardiovascular Evaluation and Management of Patients
Undergoing Noncardiac Surgery. Circulation. doi: https://doi.org/10.1161/cir.
0000000000000404
National Institute for Health and Care Excellence (2015). Peripheral arterial
disease. Available online at: https://cks.nice.org.uk/peripheral-arterial-disease.
Accessed 8 Sept 2019
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Wong et al. CVIR Endovascular            (2019) 2:37 Page 7 of 7
